These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 21287607)
1. Kinetics, in silico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: the role of water molecules examined. Hayes JM; Skamnaki VT; Archontis G; Lamprakis C; Sarrou J; Bischler N; Skaltsounis AL; Zographos SE; Oikonomakos NG Proteins; 2011 Mar; 79(3):703-19. PubMed ID: 21287607 [TBL] [Abstract][Full Text] [Related]
2. An evaluation of indirubin analogues as phosphorylase kinase inhibitors. Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215 [TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations. Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525 [TBL] [Abstract][Full Text] [Related]
5. K252a is a potent and selective inhibitor of phosphorylase kinase. Elliott LH; Wilkinson SE; Sedgwick AD; Hill CH; Lawton G; Davis PD; Nixon JS Biochem Biophys Res Commun; 1990 Aug; 171(1):148-54. PubMed ID: 2393389 [TBL] [Abstract][Full Text] [Related]
6. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding. Alexacou KM; Hayes JM; Tiraidis C; Zographos SE; Leonidas DD; Chrysina ED; Archontis G; Oikonomakos NG; Paul JV; Varghese B; Loganathan D Proteins; 2008 May; 71(3):1307-23. PubMed ID: 18041758 [TBL] [Abstract][Full Text] [Related]
7. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. Muñoz C; Adasme F; Alzate-Morales JH; Vergara-Jaque A; Kniess T; Caballero J J Mol Graph Model; 2012 Feb; 32():39-48. PubMed ID: 22070999 [TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics approach to probe PKCβII-ligand interactions and influence of crystal water molecules on these interactions. Grewal BK; Bhat J; Sobhia ME Expert Opin Ther Targets; 2015 Jan; 19(1):13-23. PubMed ID: 25363346 [TBL] [Abstract][Full Text] [Related]
9. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. Lamers MB; Antson AA; Hubbard RE; Scott RK; Williams DH J Mol Biol; 1999 Jan; 285(2):713-25. PubMed ID: 9878439 [TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2. Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497 [TBL] [Abstract][Full Text] [Related]
11. Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor. Nisha CM; Kumar A; Vimal A; Bai BM; Pal D; Kumar A J Mol Graph Model; 2016 Apr; 65():100-7. PubMed ID: 26967552 [TBL] [Abstract][Full Text] [Related]
12. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design. Shen M; Zhou S; Li Y; Li D; Hou T Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296 [TBL] [Abstract][Full Text] [Related]
13. Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex. Kosmopoulou MN; Leonidas DD; Chrysina ED; Bischler N; Eisenbrand G; Sakarellos CE; Pauptit R; Oikonomakos NG Eur J Biochem; 2004 Jun; 271(11):2280-90. PubMed ID: 15153119 [TBL] [Abstract][Full Text] [Related]
15. Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Mashkani B; Griffith R; Ashman LK Bioorg Med Chem; 2010 Mar; 18(5):1789-97. PubMed ID: 20156689 [TBL] [Abstract][Full Text] [Related]
16. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Vankayalapati H; Bearss DJ; Saldanha JW; Muñoz RM; Rojanala S; Von Hoff DD; Mahadevan D Mol Cancer Ther; 2003 Mar; 2(3):283-94. PubMed ID: 12657723 [TBL] [Abstract][Full Text] [Related]
17. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies. Tsirkone VG; Tsoukala E; Lamprakis C; Manta S; Hayes JM; Skamnaki VT; Drakou C; Zographos SE; Komiotis D; Leonidas DD Bioorg Med Chem; 2010 May; 18(10):3413-25. PubMed ID: 20430629 [TBL] [Abstract][Full Text] [Related]
18. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol. Tsitsanou KE; Hayes JM; Keramioti M; Mamais M; Oikonomakos NG; Kato A; Leonidas DD; Zographos SE Food Chem Toxicol; 2013 Nov; 61():14-27. PubMed ID: 23279842 [TBL] [Abstract][Full Text] [Related]
19. Oxime-dipeptides as anticholinesterase, reactivator of phosphonylated-serine of AChE catalytic triad: probing the mechanistic insight by MM-GBSA, dynamics simulations and DFT analysis. Chadha N; Tiwari AK; Kumar V; Lal S; Milton MD; Mishra AK J Biomol Struct Dyn; 2015; 33(5):978-90. PubMed ID: 24805972 [TBL] [Abstract][Full Text] [Related]
20. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. Schulze-Gahmen U; De Bondt HL; Kim SH J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]